Current cancer therapies targeting YAP/TAZ include inhibiting YAP/TAZ–TEAD interactions, targeting TEAD structure, targeting other YAP/TAZ‐related complex (e.g., BRD4), and targeting upstream mechanical elements (e.g., Rho/ROCK, Src) [304, 305, 306]. Here, RHO is linked to cancer.